Abstract: The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane for preventing or treating radiotherapy-related and chemotherapy-related mucositis, induced by radiotherapy or combined radiochemotherapy, comprising an effective amount of an antiradical compound mixed with a vehicle, which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled status.

Abstract: A pharmaceutical composition including an efficient amount of a compound selected among the compounds of formulae (I) and (Ia). The compounds have interesting cytotoxic properties leading to a therapeutic use as antitumoral medicines.

Abstract: A non-cytotoxic pharmaceutical composition acting on the proliferation of clonogenic cells in malignant tumors and including an efficient amount of a compound selected among the compounds of formula (I) and (Ia).

Abstract: The invention concerns a pharmaceutical composition having an activity on the proliferation of clonogenic cells in tumours and comprising an efficient amount of a compound selected among the compounds of formulae (I) and (Ia) wherein: X, R1, R2, R3, R4, R5, R6 are as defined in claim 1.

Abstract: A peptide having the following amino acid sequence:     Thr-X1-Leu-Asp-Ile-X2-X3-Asp-Leu-X4-Glu-X5-                      5               10 Arg-Leu-Lys-Tyr-Tyr-X6-X7-Arg-Lys-Glu-Phe-Leu-X8-          15               20                  25 X9-X10-Leu-Gly (SEQ ID NO: 1) wherein X1=Gln or Glu; X2=Leu or Lys; X3=Arg or Lys; X4=Phe or Tyr; X5=Leu or Lys; X6=Gly or Glu; X7=Leu or Glu; X8=Leu or Glu; X9=Gln or Lys; X10=Met or Nle; and its pharmaceutically acceptable protected deri

Abstract: The present invention relates to a process for administering an active principle to a patient transdermally, which comprises the formation of a film on the patient's skin, by applying to the skin a liquid solution which consists essentially of: a) a lipophilic active principle, b) from 2.5 to 25% by weight of a silicone-based adhesive polymer composition, c) from 0 to 25% by weight of an absorption promoter, and d) from 25 to 95% by weight of volatile solvents comprising volatile silicones.

Abstract: The invention concerns a method for preparing quinoline-5,8-diones of formula (I) wherein R1, R2 and R3 are as defined in claim 1, by light-induced oxygenation of a 8-hydroxyquinoline.

Abstract: The invention concerns compounds of formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein. Said compounds are useful in therapy as antithrombotic agents.

Abstract: Novel compounds which are inhibitors of the binding of fibrinogen to the Gp iib/iiia platelet receptors, and which can be used therapeutically as antithrombotic agents.

Abstract: Novel compounds which are inhibitors of the binding of fibrinogen to the Gp IIb/IIIa platelet receptors, and which can be used therepeutically as antithrombotic agents

Abstract: The invention relates to the use of a compound selected from: [&agr;-(tert-butylaminomethyl)-3,4-dichlorobenzyl]thioacetamide and its laevorotatory isomer, [&agr;-(tert-amylaminomethyl)-3,4-dichlorobenzyl]thioacetamide and its isomers, [&agr;-(1-adamantylaminomethyl)3,4-dichlorobenzyl]thioacetamide and its isomers, as well as the addition salts of these compounds with pharmaceutically acceptable acids, for inhibiting dopamine reuptake.

Abstract: Novel 1,4-DHP of the following structures are described having better therapeutic activities in coronary diseases: ##STR1## wherein n and R1 are as defined in the specification.

Abstract: The present invention relates to a process for the preparation of particles each comprising an excipient forming a matrix and at least one active ingredient uniformly distributed in the mass of said matrix, said process, which comprises the operations of extrusion and then lyophilization, being characterized in that it comprises the steps consisting of(1.) the preparation of a homogeneous mixture from(a) at least one active ingredient,(b) a physiologically acceptable hydrophilic excipient, and(c) waterto give a pasty mixture with a viscosity below 1 Pa.s, measured at room temperature (15.degree.-20.degree. C.);(2.) the extrusion of the resulting homogeneous mixture and the cutting of the extrudate to give moist particles;(3.) the freezing of the resulting particles as they fall under gravity through a stream of inert gas at a temperature below 0.degree. C.; and(4.) the freeze drying of said particles.

Abstract: The invention relates to the use of a compound selected from:?.alpha.-(tert-butylaminomethyl)-3,4-dichlorobenzyl!thioacetamide and its laevorotatory isomer,?.alpha.-(tert-amylaminomethyl)-3,4-dichlorobenzyl!thioacetamide and its isomers,?.alpha.-(1-adamantylaminomethyl)3,4-dichlorobenzyl!thioacetamide and its isomers,as well as the addition salts of these compounds with pharmaceutically acceptable acids, for inhibiting dopamine reuptake.

Abstract: The present invention relates to compounds of formula (I) wherein R.sub.1 is selected from H and 3-chloro; R.sub.2 is selected from a phenyl group and a pyridyl group; R.sub.3 and R.sub.4 are selected independently of each other from H and methyl; R.sub.5 and R.sub.6 are selected independently of each other from H and a pyridyl-methyl group or both represent an ethyl group; n=0 or 1; R.sub.1, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are not simultaneously H when R.sub.2 is phenyl. The salts of the compounds have a pyridyl group with pharmaceutical acceptable acids are also disclosed.

Abstract: The invention relates to a process which comprises the crystallization of a calcium salt of chiral (R or S) lactic acid esterified with a racemic dihydropyridine.

Abstract: The invention relates to [.alpha.-(tert.butyl aminomethyl)-3,4-dichlorobenzyl] thioacetamide of the formula: ##STR1## and its addition salts with pharmaceutically acceptable acids. These compounds can be used as antidepressants as well as to promote the feed intake.

Abstract: The present invention relates to the utilization of modafinil for the treatment of ventilation disorders of central origin such as sleep apnea.

Abstract: The present invention relates to compounds of formula: ##STR1## in which A is selected from pyrrolidino, piperidino, morpholino, 1-imidazolyl, hexamethylenimino and 1-piperazinyl groups, these groups being unsubstituted or it being possible for them to contain 1 or 2 substituents selected from C.sub.1 -C.sub.3 alkyl and C.sub.1 -C.sub.3 hydroxyalkyl groups, and the addition salts of these compounds with pharmaceutically acceptable acids.These compounds are usable in therapy as peripheral vasodilators.

Abstract: The invention relates to a compound of formula: ##STR1## and its addition salts with pharmaceutically acceptable acids. These compounds are useful in therapy as sedatives.